Stoke Therapeutics (STOK) Cash from Operations (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Cash from Operations of 60582000.0 for Q1 2026, down 145.96% year-over-year from 131827000.0 in Q1 2025, and down 98.93% quarter-over-quarter from 30454000.0 in Q4 2025.
Stoke Therapeutics (STOK) Cash from Operations (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 60582000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 145.96% year-over-year to 60582000.0; the TTM figure through Mar 2026 stood at 146824000.0 (down 311.13% YoY), while the FY2025 annual figure was 45585000.0, up 152.49% from the prior year.
- Cash from Operations for Q1 2026 stood at 60582000.0, down from 30454000.0 in the prior quarter.
- The five-year high for Cash from Operations was 131827000.0 in Q1 2025, with the low at 60582000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 21800000.0 (2023), against an average of 12634176.47.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations plunged 165.73% in 2023, then jumped 636.62% in 2025.
- Stoke Therapeutics' Cash from Operations stood at 22373000.0 in 2022, then grew by 7.71% to 20649000.0 in 2023, then declined by 12.32% to 23193000.0 in 2024, then plunged by 31.31% to 30454000.0 in 2025, then plunged by 98.93% to 60582000.0 in 2026.
- Business Quant data shows STOK's Cash from Operations at 60582000.0 in Q1 2026, 30454000.0 in Q4 2025, and 30366000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -56.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56.59 Mn |
| Jun 30, 2026 | -56.59 Mn |
| Mar 31, 2026 | -60.58 Mn |
| Mar 31, 2026 | -60.58 Mn |
| Dec 31, 2025 | -30.45 Mn |
| Dec 31, 2025 | -30.45 Mn |
| Sep 30, 2025 | -30.37 Mn |
| Sep 30, 2025 | -30.37 Mn |
| Jun 30, 2025 | -25.42 Mn |
| Jun 30, 2025 | -25.42 Mn |
| Mar 31, 2025 | 131.83 Mn |
| Mar 31, 2025 | 131.83 Mn |
| Dec 31, 2024 | -23.19 Mn |
| Dec 31, 2024 | -23.19 Mn |
| Sep 30, 2024 | -21.62 Mn |
| Sep 30, 2024 | -21.62 Mn |
| Jun 30, 2024 | -17.48 Mn |
| Jun 30, 2024 | -17.48 Mn |
| Mar 31, 2024 | -24.57 Mn |
| Mar 31, 2024 | -24.57 Mn |